NCT00679029 2023-12-11
Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer
University of Nebraska
Phase 2 Terminated
Clinical Trials
7 trialsNCT03329378 2023-08-22
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated
NCT02685111 2020-07-31
Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)
Asan Medical Center
Phase 2 Terminated
NCT00063934 2019-03-05
Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT02650635 2018-09-05
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
Mayo Clinic
Phase 1 Terminated
NCT01498588 2016-10-03
Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Emory University
Phase 2 Terminated
NCT00346229 2016-03-22
Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer
Duke University
Phase 1 Terminated